Docality.com Logo
 
Dr. Christine  Laramee  Md image

Dr. Christine Laramee Md

1180 Ponce De Leon Blvd Ste 401 Jsa Ponce De Leon Blvd Primary Care
Clearwater FL 33756
727 813-3171
Medical School: Other - 1992
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: Yes
License #: ME69487
NPI: 1467487967
Taxonomy Codes:
207Q00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Christine Laramee is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99203 Description:Office/outpatient visit new Average Price:$158.46 Average Price Allowed
By Medicare:
$105.73
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$156.09 Average Price Allowed
By Medicare:
$104.00
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$106.05 Average Price Allowed
By Medicare:
$70.42
HCPCS Code:Q2036 Description:Flulaval vacc, 3 yrs & >, im Average Price:$35.00 Average Price Allowed
By Medicare:
$9.51
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$32.21 Average Price Allowed
By Medicare:
$14.05
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$35.73 Average Price Allowed
By Medicare:
$23.78
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$30.00 Average Price Allowed
By Medicare:
$19.03
HCPCS Code:36415 Description:Routine venipuncture Average Price:$11.50 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:81002 Description:Urinalysis nonauto w/o scope Average Price:$12.00 Average Price Allowed
By Medicare:
$3.62

HCPCS Code Definitions

99203
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
Q2036
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
G0008
Administration of influenza virus vaccine
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1861481368
Cardiovascular Disease (Cardiology)
1,098
1013985043
Cardiovascular Disease (Cardiology)
1,011
1720077365
Cardiovascular Disease (Cardiology)
734
1407846603
Diagnostic Radiology
677
1043291982
Pulmonary Disease
602
1194716431
Cardiovascular Disease (Cardiology)
566
1346271145
Nephrology
412
1427048081
Cardiovascular Disease (Cardiology)
347
1407846066
Cardiac Electrophysiology
324
1013907435
Diagnostic Radiology
322
*These referrals represent the top 10 that Dr. Laramee has made to other doctors

Publications

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. - Postgraduate medicine
Overactive bladder (OAB) is a prevalent, chronic condition that can negatively affect health-related quality of life (HRQL). Treatment goals are to improve symptoms and HRQL. We assessed the efficacy of solifenacin in OAB patients using several patient-reported outcome (PRO) measures, with a focus on urgency severity. Results for the primary endpoint, reductions in daily urgency episodes, and other bladder-diary variables have been recently reported.In this 12-week multicenter trial, 739 patients (aged >or= 18 years) were randomized to flexibly dosed solifenacin (5/10 mg) or placebo. Prespecified secondary PRO measures included the Indevus Urgency Severity Scale (IUSS), Urgency Perception Scale (UPS), Patient Perception of Bladder Condition (PPBC), and Overactive Bladder Questionnaire (OAB-q). Appropriate statistical tests compared treatment-group differences in continuous and categorical data.In the full analysis set, patients who received solifenacin (n = 357) versus placebo (n = 350) showed significant improvements on the IUSS and UPS; treatment-group differences were 0.4 (P < 0.0001) and 0.2 (P = 0.0018), respectively. On the PPBC, significantly more patients taking solifenacin (66%) than placebo (48%) perceived fewer bladder-related problems (P < 0.0001) by week 12. On the OAB-q, solifenacin was superior to placebo for the Symptom Bother and total HRQL scales and for 3 of the 4 HRQL domains at study end (P
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. - Clinical therapeutics
This study evaluated the use of solifenacin in patients experiencing residual urgency symptoms during treatment with tolterodine extended release (ER) 4 mg for overactive bladder (OAB).This was a 12-week, multicenter, openlabel, flexible-dose study of the efficacy, tolerability, and effects on health-related quality of life (HRQL) of solifenacin in patients aged >or=18 years who had symptoms of OAB for >or=3 months, had been treated with tolterodine ER 4 mg for >or=4 weeks, and wished to switch therapy because of a lack of sufficient subjective improvement in urgency. At baseline (before washout of tolterodine), patients had to have >or=3 urgency episodes/24 hours. After >or=14 days' washout of tolterodine, all patients received oral solifenacin 5 mg/d, with the option of a dose increase to 10 mg at weeks 4 and 8. On 3 consecutive days before the prewashout, postwashout (no drug treatment for OAB), and week 4, 8, and 12 visits (during and at the end of treatment with solifenacin), patients used a bladder diary to document daily symptoms of urgency, urge incontinence, frequency, nocturia, and nocturnal voids. Changes in these measures at study end were compared with prewashout and postwashout values. The Patient Perception of Bladder Condition (PPBC) and Overactive Bladder Questionnaire (OAB-q) were used to assess patient-reported outcomes at prewashout, postwashout, and week 12. Tolerability was evaluated based on the nature, frequency, and severity of observed or reported adverse events (AEs).Of 606 patients screened, 441 received study medication (mean [SD] age, 61.4 [13.8] years; 88.9% white; 88.2% female). Diary-documented urgency changed from a mean of 6.0 episodes/24 hours at prewashout to 2.6 episodes/24 hours at study end, a mean decrease of 3.4 episodes/24 hours (95% CI, -3.8 to -3.0; P < 0.001). The frequency of all other diary variables was also significantly reduced from prewashout to study end (P < 0.001). The mean PPBC score changed from 4.2 points at prewashout to 3.0 points at study end, a mean improvement of 1.2 points (95% CI, -1.3 to -1.1; P < 0.001). Changes in all OAB-q scales and domains (symptom bother, coping, concern, sleep, social interaction, and total HRQL) from prewashout and postwashout to study end were also statistically significant (P < 0.001). Treatment-emergent AEs were mainly mild or moderate (237/261 [90.8%]) and led to few discontinuations (16/441 [3.6%]). Treatment-emergent AEs included anticholinergic AEs such as dry mouth (77 [17.5%]), constipation (51 [11.6%]), and blurred vision (10 [2.3%]).Among these patients with residual urgency after treatment with tolterodine ER 4 mg, solifenacin was associated with significant improvements in urgency and other diary-documented symptoms of OAB. Patients receiving solifenacin also had significant improvements in HRQL and the perceived bother of OAB.

Map & Directions

1180 Ponce De Leon Blvd Ste 401 Jsa Ponce De Leon Blvd Primary Care Clearwater, FL 33756

Nearby Doctors

1601 South Highland Ave.
Clearwater, FL 33756
727 855-5437
300 Pinellas St Ms19a
Clearwater, FL 33756
727 627-7415
1055 S Fort Harrison Ave
Clearwater, FL 33756
727 477-7786
1106 Druid Rd South Ste 301
Clearwater, FL 33756
727 465-5681
613 S Myrtle Ave
Clearwater, FL 33756
727 414-4526
455 Pinellas St Suite 400
Clearwater, FL 33756
727 451-1991
1106 Druid Rd S Suite 302
Clearwater, FL 33756
727 413-3711
300 Pinellas St Ms 47
Clearwater, FL 33756
727 627-7908
1100 S. Fort Harrison Jsa Fort Harrison Primary Care
Clearwater, FL 33756
727 423-3126